PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $3,335,000 | +48.8% | 38,158 | -36.7% | 0.04% | +50.0% |
Q1 2017 | $2,241,000 | +17.9% | 60,252 | -2.6% | 0.03% | +16.7% |
Q4 2016 | $1,900,000 | +48.9% | 61,874 | +225.1% | 0.02% | +50.0% |
Q3 2016 | $1,276,000 | +319.7% | 19,034 | +371.7% | 0.02% | +300.0% |
Q3 2015 | $304,000 | -35.5% | 4,035 | 0.0% | 0.00% | -33.3% |
Q2 2015 | $471,000 | -83.1% | 4,035 | -65.9% | 0.01% | -81.2% |
Q1 2015 | $2,791,000 | +213.2% | 11,820 | +151.2% | 0.03% | +220.0% |
Q4 2014 | $891,000 | -20.6% | 4,705 | 0.0% | 0.01% | -23.1% |
Q3 2014 | $1,122,000 | +118.7% | 4,705 | -39.5% | 0.01% | +116.7% |
Q2 2014 | $513,000 | -36.7% | 7,775 | 0.0% | 0.01% | -40.0% |
Q1 2014 | $810,000 | -12.5% | 7,775 | -13.1% | 0.01% | -9.1% |
Q4 2013 | $926,000 | +19.5% | 8,945 | -38.1% | 0.01% | +57.1% |
Q3 2013 | $775,000 | +10.9% | 14,450 | -8.3% | 0.01% | 0.0% |
Q2 2013 | $699,000 | – | 15,750 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 207,500 | $21,609,000 | 4.97% |
WEATHERBIE CAPITAL, LLC | 250,296 | $26,066,000 | 2.47% |
Redmile Group, LLC | 172,092 | $17,922,000 | 2.14% |
Tekla Capital Management LLC | 185,820 | $19,351,000 | 1.93% |
Iguana Healthcare Management, LLC | 35,000 | $3,645,000 | 1.68% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $592,210,000 | 1.62% |
Atika Capital Management LLC | 11,350 | $1,182,000 | 1.01% |
Eventide Asset Management | 44,900 | $4,676,000 | 0.73% |
Ghost Tree Capital, LLC | 11,330 | $1,180,000 | 0.70% |
BB BIOTECH AG | 117,991 | $12,288,000 | 0.63% |